search
Back to results

Nebivolol, Lifestyle Modification and Arterial Stiffness

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Nebivolol
Lifestyle Modification
Nebivolol plus Lifestyle Modification
Sponsored by
Virginia Polytechnic Institute and State University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Stage 1 hypertension
  • 40-75 years
  • Weight stable (+/-2 kg)
  • Sedentary to recreationally active
  • Willing to be randomized to one of three arms
  • Verbal and written consent
  • Approval by medical director

Exclusion Criteria:

  • Blood pressure outside stated range
  • Diabetes or taking diabetes medications
  • Total cholesterol >6.2 mmol/L; triglycerides >4.5 mmol/L
  • Past or current ischemic heart disease, stroke, respiratory disease, endocrine or metabolic disease, neurological disease, or hematological-oncological disease
  • Medications (including but not limited to antihypertensives, statins or other with anti-inflammatory actions) or antioxidant vitamins or supplements
  • Known allergy or hypersensitivity to nebivolol or any of its components
  • Inability to perform regular physical activity or participate in other components of lifestyle modification
  • Pregnant or planning to become pregnant

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Active Comparator

    Experimental

    Arm Label

    Nebivolol

    Lifestyle Modification

    Nebivolol plus Lifestyle Modification

    Arm Description

    Subjects will be provided with daily 5 mg of nebivolol for the first 2 weeks. Subjects receive additional daily doses of 10 mg nebivolol for the remainder of the study period. The dose remains at 5 mg per day, however, if BP falls below 110/70 during the first 2 weeks. Subjects will continue taking the drug during the 2-week follow-up period.

    Subjects will receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals were instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 minutes per week of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conformed to the Dietary Approach to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contained 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein. Sodium consumption was set at 2,400 mg/day for all subjects.

    Subjects begin with 5 mg/day of nebivolol and increase to 10 mg/day if brachial blood pressure is greater than 120/80 mmHg during the first 2 weeks of therapy. Subjects also receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals will be instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 min/wk of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conforms to the Dietary Approaches to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contains 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein with sodium consumption set at 2,400 mg/day for all subjects.

    Outcomes

    Primary Outcome Measures

    Beta-stiffness Index
    Longitudinal B-mode images of the left common carotid artery diameter (1-2 cm proximal to the carotid bulb) were obtained over 15 consecutive cardiac cycles. Brachial blood pressure was measured via an automated sphygmomanometer. Quantification of systolic and diastolic carotid artery diameters were analyzed with the Vascular Research Tools 5 software program. Beta-stiffness index was calculated as: Beta = ln(P1/P0)/((D1-D0)/D0), where D0 represents the minimal diameter recorded during diastole, D1 represents the maximal diameter recorded during systole, P0 represents the pressure measured during diastole, and P1 represents the pressure measured during systole.

    Secondary Outcome Measures

    Insulin Sensitivity (HOMA-IR)
    The HOMA index was calculated as the product of plasma blood glucose and insulin divided by 22.5.

    Full Information

    First Posted
    July 18, 2013
    Last Updated
    January 27, 2018
    Sponsor
    Virginia Polytechnic Institute and State University
    Collaborators
    Forest Laboratories
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01920282
    Brief Title
    Nebivolol, Lifestyle Modification and Arterial Stiffness
    Official Title
    Effect of Nebivolol and Lifestyle Modification on Large Artery Stiffness in Middle-Aged and Older Hypertensive Adults
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2010 (undefined)
    Primary Completion Date
    August 2012 (Actual)
    Study Completion Date
    August 2012 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Virginia Polytechnic Institute and State University
    Collaborators
    Forest Laboratories

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Numerous anti-hypertensive drugs have been reported to be efficacious in reducing central arterial stiffness and these effects may contribute to improved outcomes in hypertensive patients. However, the results of several studies suggest that beta-blockers may actually increase arterial stiffness. In contrast, there is limited evidence to suggest that nebivolol, a third generation beta-blocker that augments release of vascular nitric oxide, reduces central arterial stiffness in hypertensive individuals. Unfortunately, only a few studies have addressed this issue and all of these studies relied on indirect, blood pressure dependent measures of arterial stiffness. In addition, none of these studies focused on middle-aged and older, obese hypertensives, a population with accelerated arterial stiffening and at risk for cardiovascular diseases. Thus, the potential utility of nebivolol as a therapy to reduce large artery stiffness, particularly among the latter population, remains unclear.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    45 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Nebivolol
    Arm Type
    Active Comparator
    Arm Description
    Subjects will be provided with daily 5 mg of nebivolol for the first 2 weeks. Subjects receive additional daily doses of 10 mg nebivolol for the remainder of the study period. The dose remains at 5 mg per day, however, if BP falls below 110/70 during the first 2 weeks. Subjects will continue taking the drug during the 2-week follow-up period.
    Arm Title
    Lifestyle Modification
    Arm Type
    Active Comparator
    Arm Description
    Subjects will receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals were instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 minutes per week of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conformed to the Dietary Approach to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contained 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein. Sodium consumption was set at 2,400 mg/day for all subjects.
    Arm Title
    Nebivolol plus Lifestyle Modification
    Arm Type
    Experimental
    Arm Description
    Subjects begin with 5 mg/day of nebivolol and increase to 10 mg/day if brachial blood pressure is greater than 120/80 mmHg during the first 2 weeks of therapy. Subjects also receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals will be instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 min/wk of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conforms to the Dietary Approaches to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contains 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein with sodium consumption set at 2,400 mg/day for all subjects.
    Intervention Type
    Drug
    Intervention Name(s)
    Nebivolol
    Other Intervention Name(s)
    Bystolic
    Intervention Type
    Other
    Intervention Name(s)
    Lifestyle Modification
    Other Intervention Name(s)
    Weight loss, Sodium restriction, Physical activity
    Intervention Type
    Other
    Intervention Name(s)
    Nebivolol plus Lifestyle Modification
    Other Intervention Name(s)
    Bsytolic, Weight Loss, Sodium restriction, Physical activity
    Primary Outcome Measure Information:
    Title
    Beta-stiffness Index
    Description
    Longitudinal B-mode images of the left common carotid artery diameter (1-2 cm proximal to the carotid bulb) were obtained over 15 consecutive cardiac cycles. Brachial blood pressure was measured via an automated sphygmomanometer. Quantification of systolic and diastolic carotid artery diameters were analyzed with the Vascular Research Tools 5 software program. Beta-stiffness index was calculated as: Beta = ln(P1/P0)/((D1-D0)/D0), where D0 represents the minimal diameter recorded during diastole, D1 represents the maximal diameter recorded during systole, P0 represents the pressure measured during diastole, and P1 represents the pressure measured during systole.
    Time Frame
    12 weeks
    Secondary Outcome Measure Information:
    Title
    Insulin Sensitivity (HOMA-IR)
    Description
    The HOMA index was calculated as the product of plasma blood glucose and insulin divided by 22.5.
    Time Frame
    12 weeks
    Other Pre-specified Outcome Measures:
    Title
    Oxidized LDL Concentration
    Time Frame
    12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    40 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Stage 1 hypertension 40-75 years Weight stable (+/-2 kg) Sedentary to recreationally active Willing to be randomized to one of three arms Verbal and written consent Approval by medical director Exclusion Criteria: Blood pressure outside stated range Diabetes or taking diabetes medications Total cholesterol >6.2 mmol/L; triglycerides >4.5 mmol/L Past or current ischemic heart disease, stroke, respiratory disease, endocrine or metabolic disease, neurological disease, or hematological-oncological disease Medications (including but not limited to antihypertensives, statins or other with anti-inflammatory actions) or antioxidant vitamins or supplements Known allergy or hypersensitivity to nebivolol or any of its components Inability to perform regular physical activity or participate in other components of lifestyle modification Pregnant or planning to become pregnant
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Kevin P Davy, Ph.D.
    Organizational Affiliation
    Virginia Polytechnic Institute and State University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Nebivolol, Lifestyle Modification and Arterial Stiffness

    We'll reach out to this number within 24 hrs